Shifting to the adaptive immune system, IDH mutation confers an immunologically quiescent phenotype than wild-type counterparts, with fewer tumor-infiltrating lymphocytes (TILs) and reduced protein expression of programmed death ligand 1 (PD-L1). The gene discussed is IDH2; the disease is neoplasm.